ReviewCurrent opinion in nephrology and hypertension2015
Metabolomics and renal disease.
Review in Current opinion in nephrology and hypertension, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05719714 (Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease), which is not on this map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease
Who cites it
27 citing papers in PubMed, 48 citations in OpenAlex.
- NLRP3 inflammasome and lipid metabolism analysis based on UPLC-Q-TOF-MS in gouty nephropathy.International journal of molecular medicine · 2019Trial
- Causal Effect of Kidney Function on Lipid Metabolism: An Integrated Population-Scale Observational Analysis and Mendelian Randomization Study.Kidney medicine · 2026Article
- Plasma Metabolites Associated with CKD Stage in Autosomal Dominant Tubulointerstitial Kidney Disease.Kidney360 · 2026Article
- Integration of digital physicalomics and dual-fluid metabolomics flux ratios reveals tubular secretory dysfunction in early diabetic kidney disease.Frontiers in endocrinology · 2026Article
- Metabolomics of Sepsis and Acute Kidney Injury in Infants and Children: Current Challenges in Prevention, Diagnosis, and Management.Infectious diseases and therapy · 2025Review
- Serum and Urine Metabolites and Kidney Function.Journal of the American Society of Nephrology : JASN · 2024Article
- Current and Novel Biomarkers of Progression Risk in Children with Chronic Kidney Disease.Nephron · 2024Review
- Remote effects of kidney drug transporter OAT1 on gut microbiome composition and urate homeostasis.JCI insight · 2023Article
- Urine myo-inositol as a novel prognostic biomarker for diabetic kidney disease: a targeted metabolomics study using nuclear magnetic resonance.Kidney research and clinical practice · 2023Article
- Amino acid analysis as a method of discovering biomarkers for diagnosis of diabetes and its complications.Amino acids · 2023Review
- Assessment of uremic toxins in advanced chronic kidney disease patients on maintenance hemodialysis by LC-ESI-MS/MS.Metabolomics : Official journal of the Metabolomic Society · 2023Article
- Untargeted Metabolomic Plasma Profiling of Emirati Dialysis Patients with Diabetes versus Non-Diabetic: A Pilot Study.Biomolecules · 2022Article
- Serum Biomarkers for Chronic Renal Failure Screening and Mechanistic Understanding: A Global LC-MS-Based Metabolomics Research.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Perspectives in systems nephrology.Cell and tissue research · 2021Review
- The Dysregulation of Eicosanoids and Bile Acids Correlates with Impaired Kidney Function and Renal Fibrosis in Chronic Renal Failure.Metabolites · 2021Article
- Effects of myocardial ischemia/reperfusion injury on plasma metabolomic profile during aging.Aging cell · 2021Article
- Identification of Potential Biomarkers of Chronic Kidney Disease in Individuals with Diabetes: Protocol for a Cross-sectional Observational Study.JMIR research protocols · 2020Article
- Urine Metabolomics Analysis in Patients With Normoalbuminuric Diabetic Kidney Disease.Frontiers in physiology · 2020Article
- Metabolomics technology and bioinformatics for precision medicine.Briefings in bioinformatics · 2019Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
purpose of reviewThis review summarizes recent metabolomics studies of renal disease, outlining some of the limitations of the literature to date. RECENT
findingsThe application of metabolomics in nephrology research has expanded from the initial analyses of uremia to include both cross-sectional and longitudinal studies of earlier stages of kidney disease. Although these studies have nominated several potential markers of incident chronic kidney disease (CKD) and CKD progression, a lack of overlap in metabolite coverage has limited the ability to synthesize results across groups. Furthermore, direct examination of renal metabolite handling has underscored the substantial impact kidney function has on these potential markers (and many other circulating metabolites). In experimental studies, metabolomics has been used to identify a signature of decreased mitochondrial function in diabetic nephropathy and a preference for aerobic glucose metabolism in polycystic kidney disease. In each case, these studies have outlined novel therapeutic opportunities. Finally, as a complement to the longstanding interest in renal metabolite clearance, the microbiome has been increasingly recognized as the source of many plasma metabolites, including some with potential functional relevance to CKD and its complications. SUMMARY: The high-throughput, high-resolution phenotyping enabled by metabolomics technologies has begun to provide insight on renal disease in clinical, physiologic, and experimental contexts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.